Myristin is a relatively new discovery of a natural substance, cetyl myristoleate (SEE-till mir-is-TOL-e-ate). Cetyl Myristoleate (CM) was discovered by Harry Diehl while on a quest to find a cure for arthritis. In the relatively short time since it’s’ discovery, cetyl myristoleate (CM) has shown great promise in the fight against degenerative joint disease because it helps the body heal damaged joints while relieving pain. CM seems to function in several very different capacities, but primarily as a surfactant, or lubricant. Just like a rusty door hinge will move freely after lubrication, CM lubricates the joint for increased mobility. As osteoarthritis progresses and the bone surfaces become less well protected by cartilage, joint pain gradually increases. However, just as a rusty door hinge will eventually work after a little WD-40 creates a low-friction surface, joint mobility increases and pain decreases with the joint lubricating action of CM.

With pain relief comes increased mobility of the joint, which is actually the proper environment for the production of new cartilage. Both osteoarthritis and rheumatoid arthritis sufferers report striking improvement with cetyl myristoleate (CM), but it is important to note that there is significant improvement when cetyl myristoleate therapy is supported by supplementation with glucosamine sulfate, chondroitin sulfate, MSM.

In a recent study, patients received cetyl myristoleate, or cetyl myristoleate and GC-MSM, or a placebo. Clinical assessment included radiological test and other studies. Results were 63% improvement for the cetyl myristoleate group, 87% for the cetyl myristoleate plus GC-MSM group and 15% for the placebo group. Based on Diehl’s research a total dose of 12-15 grams, over a 17-day period) is effective. One 17-day course, 3 capsules per day, should be enough for most individuals; others may need two, three, or four courses. Each bottle of Myristin contains 51 Softgel capsules.